Full Breakdown
Revised Hepatitis B Birth-Dose Guidance Sparks Modeling Warnings
By Drooid · · How we work
Core Event: Center for Disease Control (CDC)’s 2025-2026 Shift in Birth-Dose Policy
In January 2025 the U.S. Centers for Disease Control and Prevention altered its recommendation that every newborn receive a hepatitis B vaccine at birth. The new guidance limited vaccination to infants whose mothers were known to be infected or whose hepatitis B status was unknown. A December 2025 advisory committee later suggested deferring the first dose until infants were at least two months old, and in January 2026 the CDC adopted a “shared clinical decision-making” approach for babies whose mothers tested negative. A federal judge halted the changes in March 2026; the legal dispute remains unresolved.
Background & Context
Since the early 1990s the United States has administered the hepatitis B birth dose within 24 hours of delivery, a practice credited with a reported 99 % drop in infant infections. The American Academy of Pediatrics continues to endorse universal birth-dose vaccination, citing the high risk of chronic infection when infants acquire hepatitis B early in life.
Data & Statistics
- Household exposure study (June 16, 2023): Researchers examined 158 000 children under five in 131 000 Northern California households. 2 024 children (?1.3 %) lived with a person with active hepatitis B; 58 % of exposures came from a non-maternal household member. All infants born to infected mothers were vaccinated within seven days, whereas 93.5 % of those exposed to another carrier received the vaccine. Approximately 640 000 U.S. adults live with chronic hepatitis B, and 90 % of infants infected in the first year develop chronic disease.
- Modeling study of a 3.6 million-birth cohort: Deferring the first dose to two months was projected to raise chronic hepatitis B infections by 19 % (from 255 to 303 cases). A shared-decision-making scenario was projected to increase infections by 83 % (to 467 cases). Corresponding adult-susceptibility estimates rose from 232 000 under universal birth-dose vaccination to 474 000 with delayed dosing and 1.8 million with shared decision-making.
Official Statements & Responses
- The American Academy of Pediatrics reaffirmed its recommendation that all infants receive the hepatitis B vaccine within 24 hours of birth, followed by the standard series.
Criticism & Opposition
- Dr. Alok Patel, Stanford, warned that the policy shift “creates confusion” and that many families interpret the change as making vaccination “optional.”
- Dr. Paul Offit, Children’s Hospital of Philadelphia, called for universal birth-dose vaccination, emphasizing that “all newborns should be given a birth dose of hepatitis B vaccine.”
Verbatim Quotes
- “The hepatitis B vaccine is a safe and effective way to protect against HBV infection,” — Karen Jacobson
- “We found that, even under the most optimistic conditions, the new recommendations could increase childhood hepatitis B infections by more than 80% and would result in more than half of children being susceptible to hepatitis B infection as they enter adulthood,” — Dr. Amir Mohareb
Conflicting Reports & Gaps
The household exposure analysis provides real-world vaccination coverage data but does not measure actual infection outcomes under the new policy. The modeling study offers projected increases in chronic infections and adult susceptibility, yet it is a simulation rather than observed evidence. Legal challenges have paused implementation of the revised CDC recommendations, leaving the ultimate public-health impact uncertain.
What’s Next
A peer-reviewed article detailing the modeling results is scheduled for publication in *Annals of Internal Medicine* on October 20, 2026. Ongoing litigation in Massachusetts may determine whether the CDC’s shared-decision-making approach will be reinstated or replaced by universal birth-dose vaccination.